Inmune Bio (INMB) Amortizatization of Intangibles (2021 - 2024)
Inmune Bio (INMB) posted Amortizatization of Intangibles of -$6000.0 for Q4 2024, up 95.42% sequentially from -$131000.0 in Q3 2024, and down 113.33% YoY from $45000.0 in Q1 2024.
Inmune Bio (INMB) Amortizatization of Intangibles (2021 - 2024) Analysis & Trends
Inmune Bio has reported Amortizatization of Intangibles for 4 years, with the latest figure at -$6000.0 in Q4 2024.
- Quarterly Amortizatization of Intangibles fell 113.33% year-over-year to -$6000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$79000.0 (down 135.27% YoY) and the FY2024 annual result came in at -$79000.0, down 135.27% from the prior year.
- Amortizatization of Intangibles improved to -$6000.0 in Q4 2024 per INMB's latest filing, from -$131000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $68000.0 in Q4 2022 and troughed at -$131000.0 in Q3 2024.
- A 4-year average of $35285.7 and a median of $55000.0 in 2022 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2023 and 2024: Amortizatization of Intangibles grew 19.64% in 2023, then tumbled 342.59% in 2024.
- Over 4 years, Amortizatization of Intangibles stood at $57000.0 in 2021, then rose by 19.3% to $68000.0 in 2022, then slumped by 33.82% to $45000.0 in 2023, then sank by 113.33% to -$6000.0 in 2024.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered -$6000.0, -$131000.0, and $24000.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -6,000.00 |
| Dec 31, 2024 | -6,000.00 |
| Sep 30, 2024 | -131,000.00 |
| Sep 30, 2024 | -131,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Jun 30, 2024 | 24,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Mar 31, 2024 | 34,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Dec 31, 2023 | 45,000.00 |
| Sep 30, 2023 | 54,000.00 |
| Sep 30, 2023 | 54,000.00 |
| Jun 30, 2023 | 58,000.00 |
| Jun 30, 2023 | 58,000.00 |
| Mar 31, 2023 | 67,000.00 |
| Mar 31, 2023 | 67,000.00 |
| Dec 31, 2022 | 68,000.00 |
| Dec 31, 2022 | 68,000.00 |
| Sep 30, 2022 | 58,000.00 |
| Sep 30, 2022 | 58,000.00 |